Orphan receptor IL-17RD tunes IL-17A signalling and is required for neutrophilia by Mellett, Mark et al.
ARTICLE
nATuRE CommunICATIons | 3:1119 | DoI: 10.1038/ncomms2127 | www.nature.com/naturecommunications
© 2012 Macmillan Publishers Limited. All rights reserved.
Received 11 Jul 2012 | Accepted 7 sep 2012 | Published 9 oct 2012 DOI: 10.1038/ncomms2127
Interleukin-17A, the prototypical member of the interleukin-17 cytokine family, coordinates 
local tissue inflammation by recruiting neutrophils to sites of infection. Dysregulation of 
interleukin-17 signalling has been linked to the pathogenesis of inflammatory diseases and 
autoimmunity. The interleukin-17 receptor family members (A–E) have a broad range of 
functional effects in immune signalling yet no known role has been described for the remaining 
orphan receptor, interleukin-17 receptor D, in regulating interleukin-17A-induced signalling 
pathways. Here we demonstrate that interleukin-17 receptor D can differentially regulate the 
various pathways employed by interleukin-17A. neutrophil recruitment, in response to in vivo 
administration of interleukin-17A, is abolished in interleukin-17 receptor D-deficient mice, 
correlating with reduced interleukin-17A-induced activation of p38 mitogen-activated protein 
kinase and expression of the neutrophil chemokine mIP-2. In contrast, interleukin-17 receptor D 
deficiency results in enhanced interleukin-17A-induced activation of nuclear factor-kappa B 
and interleukin-6 and keratinocyte chemoattractant expression. Interleukin-17 receptor D 
disrupts the interaction of Act1 and TRAF6 causing differential regulation of nuclear factor-
kappa B and p38 mitogen-activated protein kinase signalling pathways. 
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Pro-inflammatory cytokines of the interleukin-17 (IL-17) family are secreted by cells of the activated immune system, including TH17 cells, γδ-T cells and natural killer cells, and 
contribute to host defence against extracellular pathogens1. IL-17 
signalling pathways are also implicated in the pathogenesis of auto-
immune and inflammatory diseases, and IL-17 is found in increased 
concentrations in psoriasis, rheumatoid arthritis, inflammatory 
bowel disease and the lungs of patients with allergic asthma2–5.
The IL-17 cytokine family consists of six ligands (IL-17A-F), 
which signal through five receptors (IL-17RA-E). IL-17 receptors 
are widely expressed bestowing the cytokines with broad effector 
functions6,7. To date, IL-17RA and IL-17RC have been the best- 
characterized members of the IL-17 receptor family, and IL-17RA can 
form heterodimers with IL-17RC in initiating immune responses to 
extracellular pathogens8. IL-17A and IL-17F can form homodimers 
or heterodimers and IL-17RA- and IL-17RC-deficient mice show 
impaired responsiveness to both ligands9,10. IL-17RA binds to 
IL-17A with a higher affinity than IL-17F in humans, whereas the 
converse is true of IL-17RC11. Murine IL-17RA can bind both 
IL-17A and IL-17F but murine IL-17RC can only bind IL-17F. 
Recent findings have revealed a new role for IL-17RE in intestinal 
immunity in response to bacterial infection, with IL-17RE forming 
a receptor complex with IL-17RA to bind IL-17C12–14.
IL-17A coordinates tissue inflammation and mobilizes neu-
trophils by stimulating the production of cytokines and chemokines, 
including IL-6, keratinocyte chemoattractant (KC) and macrophage 
inflammatory protein-2 (MIP-2) in mice, and IL-8 and growth- 
regulated oncogene family members in humans15–18. IL-17RA regu-
lates gene expression by activating nuclear factor-kappa B (NF-κB) 
and mitogen-activated protein kinase (MAPK) pathways18. Mem-
bers of the IL-17 receptor family share an intracellular Sef/IL-17R 
(SEFIR) domain that is important for triggering downstream sig-
nalling19. Stimulation of IL-17RA leads to an association with the 
adaptor Act1, via SEFIR–SEFIR interactions, followed by recruit-
ment and polyubiquitination of TRAF6, thus initiating downstream 
activation of NF-κB and MAPKs20,21. Recent findings have also 
detailed a messenger RNA (mRNA)-stability pathway bifurcating 
downstream of Act1 that is independent of TRAF6 (ref. 22).
Although recent studies have delineated important immunomod-
ulatory roles for the various IL-17R members, IL-17 receptor D 
(IL-17RD) remains an orphan receptor with no reported physi-
ological role in IL-17 signalling, apart from a study in which over-
expression of IL-17RD was shown to co-operate with IL-17RA23. 
IL-17RD was originally termed similar expression to fgf (Sef) due 
its coexpression with fgf genes in zebrafish embryo development24.  
Here, we describe for the first time an important physiological 
role for IL-17RD in IL-17 signalling. IL-17RD negatively regulates 
IL-17A-induced activation of NF-κB and the expression of 
pro-inflammatory genes such as IL-6. IL-17RD coordinates these 
regulatory effects by negatively regulating Act1/TRAF6 binding 
and disrupting the IL-17RA/Act1/TRAF6 signalling axis. However, 
conversely IL-17RD promotes IL-17A-induced activation of p38 
MAPK and induction of MIP-2. In vivo, the loss of IL-17A-induced 
MIP-2 expression in IL-17RD-deficient mice is associated with 
diminished IL-17A-induced neutrophil infiltration in the lungs 
and the peritoneum, whereas exogenous MIP-2 delivery restores 
neutrophilia in these mice. From these findings it is evident that 
IL-17RD differentially regulates IL-17A-induced NF-κB and MAPK 
signalling pathways, and is an important mediator in facilitating 
IL-17A-induced neutrophilia.
Results
IL-17RD knockdown increases responsiveness to IL-17A. To 
elucidate the role of IL-17RD in IL-17A signalling, we first assessed 
the effects of IL-17RD knockdown on IL-17A-induced activation 
of NF-κB. HeLa cells were co-transfected with an NF-κB-regulated 
luciferase reporter plasmid and IL-17RD-specific small interfering 
RNA (siRNA) or a scrambled control siRNA. The IL-17RD-specific 
siRNA strongly suppressed IL-17RD expression whereas the 
control siRNA was without effect (Fig. 1a). Knockdown of IL-17RD 
augmented the ability of human IL-17A to induce the expression 
of NF-κB-regulated luciferase (Fig. 1a). The control siRNA was 
without effect confirming the specificity of the effects of IL-17RD 
siRNA. Additionally, IL-17A-induced expression of the NF-κB-
responsive gene IL-6 was enhanced in IL-17RD-knockdown cells 
(Fig. 1b), consistent with an inhibitory role for IL-17RD in regulating 
IL-17A-induced activation of NF-κB. This was further confirmed 
by overexpressed IL-17RD inhibiting IL-17A-induced activation of 
NF-κB activation in HeLa cells (Fig. 1c).
To further validate these effects, we established U373 cell lines 
transduced with lentivirus to stably express IL-17RD-specific short-
hairpin RNA (shRNA) or control shRNA. Knockdown efficiency was 
regularly checked in these U373-shRNA stable cell lines and 40–60% 
knockdown of Il17rd mRNA was consistently achieved compared 
with the control-shRNA (Fig. 1d). The knockdown of IL-17RD in 
these cells resulted in augmented IL-17A-induced phosphorylation 
of IκB and upstream IKKs (Fig. 1e) and this was associated with 
enhanced NF-κB–DNA binding (Fig. 1f). Again, knockdown of IL-
17RD in this model resulted in an enhancement of IL-17A-induced 
expression of IL-6 (Fig. 1g). To further validate that augmented IL-6 
production in IL-17RD-knockdown cells is directly attributable to 
diminished expression of IL-17RD, we demonstrated that the expres-
sion of exogenous IL-17RD strongly suppressed IL-17A induction of 
IL-6 in cells stably expressing IL-17RD shRNA (Fig. 1h).
IL-17RD differentially regulates IL-17A-responsive genes. The 
above knockdown studies suggested IL-17RD to be a negative regu-
lator of IL-17A signalling. To confirm the physiological relevance of 
such a role, it was necessary to generate IL-17RD-deficient mice and 
this was achieved by gene-trap technology. The gene that encodes 
murine IL-17RD consists of 13 exons. The targeting vector disrupted 
the Il17rd gene between the first and second exons with a β-geomy-
cin-resistance gene cassette (Supplementary Fig. S1a). Il17rd − / −  
pups were born in an expected Mendelian ratio and showed no obvi-
ous phenotypic abnormalities and this is consistent with previously 
generated IL-17RD-deficient mice25. As expected, Il17rd mRNA 
expression is abolished in Il17rd − / − mice and replaced by β-Geo 
expression (Supplementary Fig. S1b). Quantitative PCR was used 
to confirm disruption of the gene encoding IL-17RD in Il17rd − / −  
murine embryonic fibroblasts (MEFs) (Supplementary Fig. S1c). 
Il17rd − / −  MEFs were used to assess a potential regulatory role for 
IL-17RD by measuring IL-6 expression in response to principal 
IL-17RA cytokines, IL-17A and IL-17F (Fig. 2a). IL-17A was the 
more efficacious inducer of IL-6 expression from MEFs from wild-
type mice and its efficacy was greatly enhanced in Il17rd − / −  MEFS. 
A more detailed characterization of the regulatory effects of IL-17RD 
on IL-17A signalling was then performed. This initially involved an 
assessment of the effects of IL-17RD deficiency on the expression 
of a number of IL-17A-responsive genes in MEFs. Similar to IL-6, 
loss of IL-17RD resulted in significantly enhanced KC expression in 
response to IL-17A (Fig. 2b). In contrast IL-17A-induced expres-
sion of the chemokine MIP-2 was diminished in Il17rd − / −  MEFs, 
indicating that IL-17RD can differentially regulate the expression 
of  IL-17A-responsive genes. This was independent of cell type as pri-
mary bone marrow-derived macrophages (BMDMs) from Il17rd − / −  
mice also displayed enhanced expression of IL-6 and KC but reduced 
expression of MIP-2 in response to IL-17A (Fig. 2c). The differen-
tial effects of loss of IL-17RD on KC and MIP-2 expression are also 
relevant to human cells as U373 cells, stably expressing IL-17RD 
shRNA, similarly showed diminished production of human MIP-2 
but increased IL-8 gene expression upon administration of human 
IL-17A (Fig. 2d). We further validated the findings in human 
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primary cells. Thus, peripheral blood mononuclear cells (PBMCs) 
were isolated from blood, obtained from healthy volunteers, and 
transfected with IL-17RD-specific and scrambled siRNAs to silence 
IL-17RD gene expression (Fig. 2e). Knockdown of IL-17RD in 
PBMCs resulted in diminished human MIP-2 production and an 
increase in IL-8 protein expression in response to IL-17A (Fig. 2e). 
These studies indicate that IL-17RD exerts differential effects on the 
expression of IL-17-responsive genes with the loss of IL-17RD lead-
ing to augmented induction of IL-6 and KC (IL-8 in human cells) 
but suppressed expression of MIP-2.
IL-17RD mediates neutrophil infiltration to the peritoneum. 
Given the above differential effects of IL-17RD on IL-17A-
responsive genes, we next probed the physiological relevance of 
these effects by evaluating IL-17A-mediated neutrophilia in both 
Il17rd + / +  and Il17rd − / −  mice. Mice were treated with recombinant 
IL-17A via intraperitoneal injection, killed 3 h post injection and 
peritoneal cells were collected from lavage. Flow cytometric analysis 
was subsequently performed on the peritoneal exudate cells (PECs) 
to quantitate the neutrophil population (Fig. 3a). The administra-
tion of IL-17A to wild-type mice induced marked neutrophil infil-
tration into the peritoneum but this was dramatically reduced in 
Il17rd − / −  mice. The greatly diminished neutrophil infiltration in 
Il17rd − / −  mice was observed at various times post IL-17A admin-
istration (Fig. 3b). The critical mediatory role for IL-17RD in facili-
tating neutrophil infiltration was selective for IL-17A signalling 
as neutrophil infiltration trigged by the bacterial chemoattractant 
peptide formyl–Met–Leu–Phe was unaffected by loss of IL-17RD 
(Fig. 3c). We next measured the expression of IL-6, KC and MIP-2 
in PECs isolated from the above treated mice. The in vivo adminis-
tration of IL-17A increased the mRNA levels of all three cytokines 
in PECs from wild-type mice and in keeping with the earlier cell-
based models, the induction of IL-6 and KC was further enhanced 
whereas MIP-2 expression was greatly diminished in PECs from 
similarly treated Il17rd − / −  mice (Fig. 3d). These findings were 
further corroborated by measuring KC and MIP-2 protein levels in 
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Figure 1 | Knockdown of human IL-17RD enhances IL-17A-induced signalling. (a) Assay of nF-κB reporter activity in HeLa cells transfected with  
IL-17RD-specific siRnA or scrambled siRnA (10, 20 nm). Forty-eight hours post transfection cells were treated with IL-17A (100 ng ml − 1) for 8 h. The 
efficiency of silencing was evaluated by immunoblotting (right panel). (b) Cell supernatants were assayed for IL-6 levels by sandwich ELIsA. (c) nF-κB 
reporter assay in HeLa cells transfected overnight with IL-17RD (100 ng) or empty vector pcDnA3.1 (EV). Transfected cells were then treated with IL-
17A (100 ng ml − 1) for 8 h. (d) Knockdown of IL-17RD mRnA in u373 cells stably transduced with control shRnA or specific IL-17RD shRnA. u373 cells 
stably transduced with control shRnA or IL-17RD-specific shRnA were treated with IL-17RA (100 ng ml − 1) as indicated. Cells lysates were subjected to 
immunoblotting with indicated antibodies (e) or nuclear extracts were assayed for nF-κB/DnA binding by electrophoretic mobility shift assay (f) or  
supernatants were analysed for IL-6 production using sandwich ELIsA (g). (h) u373 cells stably transduced with control shRnA or IL-17RD-specific 
shRnA were transfected with EV or IL-17RD (1 µg). Cells were then treated with IL-17A (100 ng ml − 1) for 24 h and IL-6 mRnA levels were evaluated by 
quantitative PCR (qPCR). Data are representative of three independent experiments (e,f) or represent mean ± s.e.m. of three independent experiments 
(a–d, g–h) with triplicate determinants (a–c, g–h). ns, nonsignificant; *P < 0.05 (student’s t test).
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lavage fluid from IL-17-treated mice. Again administration of IL-17A 
to wild-type mice caused increased lavage levels of KC and MIP2, 
with KC being further enhanced and MIP-2 diminished in similarly 
treated Il17rd − / −  mice (Fig. 3e). Given that IL-17A-induced expres-
sion of MIP-2 is greatly suppressed in Il17rd − / − mice, coupled to 
the strong chemoattractant activity of MIP-2 towards neutrophils, 
we investigated whether administration of exogenous MIP-2 could 
overcome the deficiency in IL-17A-induced neutrophilia that we 
observed in Il17rd − / −  mice. We again treated mice with IL-17A 
by intraperitoneal injection, which was followed by intraperitoneal 
injection of recombinant MIP-2 one hour later in order to evaluate 
whether MIP-2 deficiency provided an underlying basis to the phe-
notypic changes on neutrophilia in Il17rd − / −  mice. As before, the 
administration of IL-17A to wild-type mice promoted strong neu-
trophilia and this was not further enhanced by coadministration of 
MIP-2, indicating that the latter is not a limiting factor in wild-type 
mice (Fig. 3f). However, exogenous MIP-2 significantly enhanced 
neutrophilia in IL-17A-treated Il17rd − / −  mice consistent with 
our hypothesis that deficiency in MIP-2 expression in IL-17RD- 
deficient mice may be an important limiting factor underlying 
reduced neutrophilia in these animals (Fig. 3f). It is interesting to 
note that the enhanced KC expression in Il17rd − / − mice failed to 
compensate for the reduced levels of MIP-2. However, a previous 
study indicated MIP-2 to be a more potent neutrophil chemoat-
tractant than KC26. Our findings are consistent with this role for 
MIP-2 being the chief chemoattractant of neutrophils in vivo, as 
the diminished IL-17A-induced neutrophil infiltration in Il17rd − / −  
mice was associated with loss of MIP-2 expression.
IL-17RD mediates IL-17A-induced pulmonary neutrophilia. 
The key role of IL-17RD in mediating neutrophil infiltration into 
the peritoneum in response to IL-17A prompted us to examine 
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Figure 2 | IL-17RD differentially regulates expression of IL-17A-responsive genes. (a) Primary mEFs from Il17rd + / +  and Il17rd − / −  mice were treated 
with IL-17 ligands (100 ng ml − 1) as indicated and IL-6 production was assayed by ELIsA. Primary mEFs (b) and BmDms (c) from Il17rd + / +  and Il17rd − / −  
mice were incubated with IL-17A (100 ng ml − 1) as indicated. IL-6, KC and mIP-2 mRnA levels were evaluated by qPCR. (d) u373 cells, stably transduced 
with control shRnA or IL-17RD-specific shRnA, were treated with IL-17A (100 ng ml − 1) for 24 h. Human mIP-2 and IL-8 mRnA levels were evaluated 
by qPCR. (e) Primary human PBmCs were transfected with IL-17RD-specific or scrambled siRnA for 48 h and treated with human IL-17A for 24 h. The 
efficiency of gene silencing was measured by qPCR. Human mIP-2 and IL-8 protein levels were measured by ELIsA. Data represent mean ± s.e.m. of three 
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a more general role for IL-17RD in mediating tissue neutrophilia. 
To investigate this, mice were challenged with IL-17A via intrana-
sal injection to elicit pulmonary neutrophilia. Mice were killed after 
24 h and cells in the bronchoalveloar lavage (BAL) fluid were ana-
lysed (Fig. 4a). Consistent with findings from intraperitoneal injec-
tion, Il17rd − / −  mice had significantly less (P < 0.038, Student’s t test) 
lung-infiltrating neutrophils, in response to IL-17A administration, 
in the BAL fluid relative to wild-type animals (Fig. 4a). There was 
no difference in lymphocyte and monocyte numbers in BAL fluid 
between Il17rd + / +  and Il17rd − / −  mice, demonstrating a specific 
effect of IL-17RD on neutrophilia. Furthermore, histological analysis 
of lung tissue showed a significant decrease in neutrophil infiltration 
in Il17rd − / −  mice compared with Il17rd + / +  mice (Fig. 4b).
IL-17A-induced expression of IL-6, KC and MIP-2 was also 
measured in lung tissue from the above mice by quantitative 
PCR (Fig. 4c). IL-17A-induced expression of KC and IL-6 levels 
was further augmented in lung tissue from Il17rd − / −  mice rela-
tive to Il17rd + / +  mice, whereas IL-17A-induced MIP-2 expression 
was greatly reduced in lung samples from Il17rd − / −  mice. This 
is consistent with the observed absence of neutrophilia in the 
lung and reaffirms a critical role for IL-17RD as a mediator of 
neutrophilia.
IL-17RD differentially regulates NF-κB and p38 MAPK. To under-
stand the mechanism by which IL-17RD can differentially regulate 
the expression of IL-17A-responsive genes, we characterized the role 
of IL-17RD in IL-17 signalling pathways. IL-17A-induced signalling 
diverges at Act1 into TRAF6-dependent and -independent path-
ways. In the TRAF6-independent pathway, Act1 recruits TRAF2 
and TRAF5, which in turn dissociate splicing-regulatory factor 2 
from the 3′-untranslated region (3′UTR) of mRNAs, such as those 
encoding KC, thus promoting stability of the mRNA22. However, 
IL-17RD appears to lack a role in this arm of the IL-17A signal-
ling pathway as KC and MIP-2 mRNA show similar stability profiles 
in MEFs from Il17rd + / +  and Il17rd − / −  embryos (Supplementary 
Fig. S2a). In addition overexpression of IL-17RD failed to affect 
the Act1 induction of a luciferase reporter gene with 3′-UTRs from 
various IL-17-responsive genes (Supplementary Fig. S2b).
In the TRAF6-dependent pathway arm of the IL-17A pathway, 
Act1 recruits TRAF6, promoting ubiquitination of the latter and 
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and data are representative of three individual experiments (total n = 12–21) (a–c), represent mean ± s.e.m. of three independent experiments (total  
n = 8–9) (d–e) or are mean ± s.e.m. (total n = 4–9) (f). * P < 0.05; ** P < 0.01; ***P < 0.001 (student’s t test). ns, nonsignificant.
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activation of NF-κB and MAPKs. In a further effort to understand 
the mechanism(s) by which IL-17RD can exert differential regula-
tory effects on the expression of IL-17A-responsive genes, we char-
acterized the ability of IL-17A to activate the NF-κB and MAPK 
pathways in primary macrophages from Il17rd + / +  and Il17rd − / −  
mice. Loss of IL-17RD results in increased IL-17A-induced phos-
phorylation of IκB (Fig. 5a). In relation to the MAPK pathways, the 
most notable IL-17RD-mediated response was marked reduction in 
p38 MAPK phosphorylation. These differential effects of IL-17RD 
on IL-17A-induced activation of NF-κB and p38 MAPK were also 
observed in Il17rd − / −  MEFs (Supplementary Fig. S3).
As IL-17RD − / −  cells showed enhanced NF-κB activation in 
response to IL-17A, compared with their wild-type counterparts, 
we examined the effect of the loss of IL-17RD on the ubiquitination 
status of TRAF6. Polyubiquitination of TRAF6 was enhanced in 
IL-17RD-deficient cells (Fig. 5b), which is consistent with the 
increased activation of NF-κB. As IL-17RA employs Act1 to promote 
the polyubiquitination of TRAF6, we next investigated the potential 
of IL-17RD to regulate the interaction of Act1 with IL-17RA and 
TRAF6. We demonstrate that IL-17A-induced interaction of Act1 
with both TRAF6 and IL-17RA is further enhanced in IL-17RD-
deficient MEFs, consistent with a role for IL-17RD in inhibiting 
this arm of the pathway (Fig. 5c). The increased interaction of Act1 
with TRAF6 correlates with the increased polyubiquitination of 
TRAF6 and activation of NF-κB in response to IL-17A in IL-17RD- 
deficient cells. These data suggest that IL-17RD may act as a natural 
‘brake’ for IL-17A signalling by inhibiting the interaction of Act1 
with IL-17RA and TRAF6 and so blocking the TRAF6-dependent 
pathway. To determine how IL-17A-induced signalling may be able 
to overcome this regulatory effect of IL-17RD, we examined the 
effect of IL-17A on the interaction of both IL-17RA and Act1 with 
overexpressed IL-17RD. Both IL-17RA and Act1 interacted basally 
with IL-17RD in unstimulated cells and these interactions were lost 
upon IL-17A stimulation (Fig. 5d). Interestingly, the time-dependent 
loss of binding of IL-17RD to IL-17RA and Act1, in response to 
IL-17A stimulation, closely correlates with IL-17A-induced binding 
of Act1 to IL-17RA and TRAF6 (Fig. 5c). These data suggest that 
IL-17RD may sequester Act1 and serve to prevent its interaction 
with IL-17RA and TRAF6. As IL-17RA, Act1 and IL-17RD have 
SEFIR domains, we next explored whether the SEFIR domain of 
IL-17RD was crucial for its interaction with Act1 and IL-17RA. An 
IL-17RD deletion mutant, termed IL-17RD ∆C, was generated that 
lacked the C-terminal SEFIR domain and was compared with its 
full-length counterpart for the ability to interact with Act1. Full-
length IL-17RD interacted with coexpressed Act1 but IL-17RD 
∆C failed to show any detectable interaction with Act1 (Fig. 5e). 
IL-17RD ∆C also failed to mimic full-length IL-17RD in its inter-
action with IL-17RA (Supplementary Fig. S4), indicating an 
important role for the SEFIR domain of IL-17RD in facilitating 
interaction with IL-17RA and Act1. Furthermore, whereas overex-
pression of IL-17RD reduced the interaction of Act1 with TRAF6, 
IL-17RD ∆C had no effect on this interaction (Fig. 5f). These data 
are consistent with IL-17RD associating with IL-17RA and Act1 via 
a SEFIR–SEFIR interaction with this association being important 
for disrupting the Act1/TRAF6 signalling pathway. Indeed, this is 
further supported by full length IL-17RD inhibiting Act1-induced 
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Figure 4 | IL-17RD regulates IL-17A-induced neutrophil infiltration in lung tissue. (a,b) IL-17A (0.5 µg per mouse) was introduced intranasally into 
Il17rd + / +  and Il17rd − / −  mice. (a) Differential cell count data from cytospin slides depicting percentages of neutrophils, lymphocytes and monocytes in 
BAL at 4 h after IL-17A treatment. (b) Representative images of hematoxylin and eosin stained slides from lungs taken from Il17rd + / +  and Il17rd − / −  mice 
after IL-17A treatment. scale bar, 50 µm. (c) IL-17A (0.5 µg) was introduced intranasally for 24 h and lung tissue was retained to measure mRnA levels 
of IL-6, KC and mIP-2 by quantitative PCR (qPCR). Results are mean ± s.e.m. (n = 3–4 mice per group) and data are representative of three independent 
experiments (total n = 9–12) (a,b) or are mean ± s.e.m. (n = 4–6 mice per group) (c). *P < 0.05 (student’s t test).
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activation of NF-κB, whereas IL-17RD ∆C failed to show such inhib-
itory effects (Fig. 5g). Furthermore, IL-17RD was shown to have no 
effect on the TRAF6-independent mRNA stability pathway and 
indeed IL-17RD had no effect on the interaction of Act1 and IKKi 
(Supplementary Fig. S5). These findings are consistent with a model 
where IL-17RD sequesters Act1 from interacting with IL-17RA and 
TRAF6 and so negatively regulates IL-17A-induced activation of 
NF-κB. Furthermore, stimulation of cells with IL-17A leads to dis-
sociation of Act1 from IL-17RD and thereby allows interaction of 
the former with IL-17RA and TRAF6, thus triggering the NF-κB 
pathway. This provides a plausible mechanism by which IL-17RD 
can downregulate NF-κB-responsive genes such as IL-6 and KC. 
Interestingly, the sequestration of Act1 as a regulatory mechanism 
is not without precedent given that it can be targeted to prevents its 
inhibitory effects on B-cell activating factor receptor signalling27.
Intriguingly, the earlier studies above also show that IL-17RD 
mediates IL-17A-induced expression of MIP-2 and neutrophilia 
and this appears at odds with a negative role for IL-17RD in IL-17 
signalling. However, we demonstrated above that IL-17A-induced 
activation of the p38 MAPK pathway is dependent on IL-17RD and 
thus we assessed whether p38 MAPK mediates IL-17A-induced 
expression of MIP-2. IL-17A-induced activation of MIP-2 was 
abrogated in cells pretreated with the p38 MAPK inhibitor 
SB203580 (Fig. 5h). This is consistent with a previous report showing 
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Figure 5 | IL-17RD targets Act1 and differentially regulates NF-B and p38 MAPK. (a) Primary BmDms from Il17rd + / +  and Il17rd − / −  mice were 
stimulated with IL-17A (100 ng ml − 1) as indicated. Cell lysates were subjected to immunoblotting with indicated antibodies. (b) Primary mEFs from 
Il17rd + / +  and Il17rd − / −  embryos were stimulated with IL-17A (100 ng ml − 1) as indicated. Cell lysates were immunoprecipitated with anti-TRAF6 and 
treated with sDs followed by immunoblotting with indicated antibodies. (c) Primary mEFs from Il17rd + / +  and Il17rd − / −  embryos were stimulated  
with IL-17A (100 ng ml − 1) as indicated. Cell lysates were immunoprecipitated with anti-Act1 followed by immunoblotting with indicated antibodies.  
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indicated. Lysates were immunoprecipitated with anti-myc followed by immunoblotting with indicated antibodies. (e) HEK293 cells were transfected 
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overnight with Act1 (50 ng) with IL-17RD or IL-17RD ∆C (50 ng). (h) Primary BmDms from Il17rd + / +  and Il17rd − / −  mice were pre-treated for 45 min  
with sB203580 (10 µm) and then stimulated with IL-17A (100 ng ml − 1) for 3 h. mIP-2 and KC mRnA levels were evaluated by qPCR. Data are 
representative of three independent experiments (a–f) or represent mean ± s.e.m. of three independent experiments (g,h). *P < 0.05 (student’s t test).  
ns, nonsignificant.
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a requirement for p38 MAPK for MIP-2 expression in response to 
IL-17A17. Interestingly, the p38 MAPK inhibitor failed to affect KC 
expression and again this is consistent with the differential effect of 
IL-17RD on KC and MIP-2 expression.
Discussion
Although functional IL-17 cytokine signalling is associated with 
efficient clearance of extracellular pathogens, dysregulation of sig-
nalling can be damaging in exacerbating chronic inflammation and 
autoimmunity if not stringently regulated. The complexity of IL-17 
biology is due to multiple members of the IL-17 family employing 
a number of IL-17 receptors with receptor co-operativity also being 
a feature of IL-17 action. On the basis of structural similarity the 
IL-17 receptor family is constituted by five members28. To date, 
direct functional data has demonstrated a role for only four of the 
IL-17 receptors (A, B, C and E) in IL-17 signalling. Despite shar-
ing structural features with these other family members, IL-17RD 
remains an orphan receptor with no available data indicating a 
physiologically relevant role for IL-17RD in IL-17 biology. We 
now report for the first time, a regulatory role for IL-17RD in 
IL-17A-induced neutrophilia and activation of MAPK and NF-κB 
signalling pathways.
Previous findings have demonstrated that IL-17RA, -B, -C and 
-E, but not IL-17RD, are upregulated upon IL-17A stimulation7. 
Instead basal IL-17RD expression is relatively high compared 
with IL-17RA and this is consistent with our proposed role for the 
orphan receptor acting as a basal ‘braking system’ that needs to be 
relieved by IL-17A stimulation in order to manifest the activation 
of NF-κB and induction of pro-inflammatory cytokines and chem-
okines. Importantly, IL-17RD appears to act to differentially regu-
late various IL-17-responsive genes. Although IL-17RD negatively 
regulates IL-17-induced expression of pro-inflammatory genes, 
such as IL-6 and KC, it also fulfils a key mediatory role in facilitat-
ing IL-17-induced expression of other pro-inflammatory proteins 
such as MIP-2. Indeed in an inflammatory context, the latter posi-
tive role of IL-17RD in IL-17 signalling appears to be the dominant 
one at least in the context of IL-17A-induced neutrophilia, as in 
the present study IL-17RD-deficient mice show greatly diminished 
neutrophil recruitment in tissues challenged with IL-17A. We also 
provide a mechanistic basis to the differential effects of IL-17RD 
on IL-17-responive genes. We propose that IL-17RD negatively 
regulates NF-κB by sequestering Act1 and preventing its interac-
tion with IL-17RA and TRAF6, thus inhibiting ubiquitination of the 
latter. Sequestration of Act1 by IL-17RD is lost upon IL-17A stimu-
lation, suggesting that IL-17RD inhibits Act1 function in resting 
cells and that this basal braking system is relieved upon stimulation 
of cells with IL-17 allowing for downstream activation of NF-κB 
and induction of genes such as IL-6 and KC. Intriguingly, IL-17RD 
also appears to have a contrasting mediatory role in IL-17A-induced 
phosphorylation of p38 MAPK and induction of MIP-2. The latter 
is especially important in terms of a critical physiological role for 
IL-17A in mediating tissue neutrophilia. Such findings also empha-
size the complexity of the IL-17A signalling pathway. To date IL-17 
signal transduction has been divided into TRAF6-dependent and 
TRAF6-independent pathways, the former assumed to trigger acti-
vation of NF-κB and MAPKs whereas the latter regulates mRNA 
stability. However, the present study clearly shows that IL-17RD can 
differentially regulate both the NF-κB and p38 MAPK pathways. 
Although IL-17RD negatively regulates TRAF6 ubiquitination and 
thereby inhibits NF-κB, it can also employ unubiquitinated TRAF6 
to trigger activation of p38 MAPK. The exact mechanistic basis to 
these differential effects awaits full delineation.
Previously, it has been reported that IL-17RD promotes IL-17A-
induced signalling based on its ability to activate a 24p3 native 
promoter23. 24p3 or murine lipocalin-2 (also known as SIP24) is 
an IL-17-inducible gene that is dependent on NF-κB activation29. 
Such a positive role for IL-17RD in activation of a NF-κB- 
responsive promoter appears to directly contrast with our observed 
inhibitory function for IL-17RD in the NF-κB pathway. How-
ever, NF-κB recruitment to the 24p3 promoter has been reported 
to be dependent on p38 MAPK activity30 and thus the presently 
described role for IL-17RD in mediating IL-17-induced activation 
of p38 MAPK may underlie the ability of IL-17RD to activate the 
24p3 promoter23. Collectively, these data indicate that IL-17RD is 
an important functional regulator of IL-17A-induced signalling. 
Furthermore, IL-17RD is the last orphan receptor of the IL-17 
receptor family and the present study prompts renewed interest in 
identification of a potential ligand for the IL-17RD receptor. This 
study reveals the first immunomodulatory and physiological role 
of IL-17RD and represents an important advance in our increasing 
awareness of the complexity of signalling triggered by IL-17 and its 
receptors.
Methods
Mice. IL-17RD-deficient mice were generated by the German Genetrap  
Consortium using its proprietary technology (Clone ID: D065E01) (Supplemen-
tary Fig. S1a). The genetrap targeting vector, which contains a promoter-less 
reporter gene downstream of a splice acceptor and a selectable marker gene (β-Geo 
for β-Galactosidase neomycin-resistant fusion gene), was incorporated into the 
Il17rd gene after the first exon. The targeting vector contains loxP, f3 and lox5171 
sites allowing conditional mutagenesis or recombinase-mediated cassette exchange. 
After the targeting vector was transfected into embryonic stem cells, G418-resist-
ent colonies were selected and screened by PCR. Homologous recombinants were 
microinjected into female C57BL/6 background mice and heterozygous F1 progeny 
were intercrossed to obtain Il17rd − / −  mice. Il17rd + / − mice were bred to generate 
age- and sex-matched Il17rd + / +  and Il17rd − / −  mice for experiments. Breeding, 
colony expansion and maintenance were performed in the Bioresource facility of 
the National University of Ireland (NUI) Maynooth. All animals were housed in 
a barrier unit, in individually ventilated cages with high-efficiency particulate air 
filters. Animals are monitored regularly for microorganisms according to FELASA 
recommendations. All animal experiments were performed in accordance with 
the regulations and guidelines of the Irish Department of Health and protocols 
approved by the Research Ethics committee of NUI Maynooth.
Plasmids and reagents. Full-length IL-17RD was cloned from HEK293 cell 
cDNA. The primers for IL-17RD were designed based on the sequence deposited  
in GenBank (accession number AF458067). IL-17RD was tagged at the C-terminus 
with the c-Myc epitope tag by incorporating the c-Myc sequence in the reverse 
primer. Each forward and reverse primer contained Xba1 restriction sites as  
underlined: forward 5′-GCTCTAGAGCATGGCCCCGTGGCTGCAGCTCTGC 
TCCGT-3′ and reverse 5′-GCTCTAGAGCTCACAGATCTTCTTCAGAAATAA 
GTTTTTGTTCCAAAGGGGCGACCGCGTGGAGTTC-3′. The PCR product was 
purified and subsequently cloned into the pcDNA3.1/Zeo (Invitrogen). IL-17RD 
∆C was generated using the reverse primer 5′-GCTCTAGAGCTCACAGATCTTC 
TTCAGAAATAAGTTTTTGTTC ATAGCAGAGAA-3′. FLAG- and HA-tagged 
Act1 plasmids were gifts from Dr Antonio Leonardi (Federico II University of 
Naples, Italy). TRAF6 was from Tularik (San Francisco, CA) and IKKi was a gift 
from Dr Marion Butler (NUI, Maynooth, Ireland). TK Renilla-luciferase reporter 
construct (phRL-TK) was from Promega (Madison, WI). The NF-κB-luciferase 
reporter construct was a gift from Professor Luke O’Neill (Trinity College Dublin, 
Ireland). Tumour necrosis factor-α, IL-8 and β-actin 3′UTR luciferase constructs 
were gifts from Professor Andrew Bowie (Trinity College Dublin, Ireland).  
Recombinant mouse IL-17A was from R&D Systems (Minneapolis, USA) whereas 
recombinant mouse IL-17C, D, E and F were from ImmunoTools (GmbH, 
Friesoythe, Germany). Recombinant human IL-17A was from Peprotech (Rocky 
Hill, NJ, USA). Anti-phospho IκBα, anti-phospho IKK, anti-IKK, anti-phospho  
p38, anti-p38, anti-phospho ERK, anti-ERK, anti-phospho JNK, anti-JNK and 
anti-Myc antibodies were from Cell Signalling Technology Inc. (Danvers, MA). 
Anti-β-actin and anti-FLAG antibodies and Actinomycin D were supplied by  
Sigma-Aldrich. Anti-IκBα, anti-TRAF6, anti-ubiquitin, anti-Act1 and anti IL-
17RA antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA) and  
anti-HA antibody was from Covance Inc. (New Jersey, USA). Anti-CD11b, PE  
anti-Ly6G and APC anti-F4/80 antibodies were from eBioscience (San Diego, CA). 
p38 MAPK inhibitor SB203580 was from Calbiochem (Darmstadt, Germany).
Cell Culture. HeLa, HEK293 and U373 cells were cultured in Dulbecco’s modified 
Eagle’s medium supplemented with 10% (v/v) fetal bovine serum, 100 U ml − 1 
penicillin and 100 µg ml − 1 streptomycin. Cells were maintained at 37 °C in a  
humidified atmosphere of 5% CO2. For the preparation of primary MEFs, 
Il17rd + / −  mice were crossed to generate Il17rd + / +  and Il17rd − / −  embryos. 
Embryos were dissected from pregnant females at day 13 post coitum. MEFs 
were isolated by standard procedure and cultured in Dulbecco’s modified Eagle’s 
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medium supplemented with 10% (v/v) FBS for 3 days. To isolate marrow-derived 
macrophages, tibias and femurs from either Il17rd + / +  and Il17rd − / −  mice were 
removed using sterile technique and the bone marrow was flushed with fresh 
medium. To obtain macrophages, cells were plated in medium supplemented with 
M-CSF (20 ng ml − 1) and maintained at 37 °C in a humidified atmosphere of 5% 
CO2 for 4–6 days. Human PBMCs from healthy volunteers were extracted from 
buffy coats provided by the Irish Blood Transfusion Service. PBMCs were  
isolated using the Ficoll-Hypaque isolation technique and plated in complete  
RPMI 1640 medium.
Peritoneal and pulmonary administration of IL-17A. Age- and sex-matched 
Il17rd + / +  and Il17rd − / −  mice were treated with 0.5 µg of IL-17A (R&D Systems) 
by intraperitoneal injection, as previously described31, or 1 µg of the formyl– 
Met–Leu–Phe peptide (Sigma) prepared in endotoxin-free phosphate-buffered 
saline (PBS) and control mice were injected with endotoxin-free PBS. For the 
exogenous MIP-2 administration experiment mice were subjected to intraperito-
neal injection of 0.5 µg of IL-17A or PBS 1 h before the treatment with recombinant 
murine MIP-2 (30 ng) for 2 h. The peritoneal cavity was lavaged with 2 ml ice-cold 
PBS at 0–6 h post treatment. Peritoneal cells were counted and quantified by flow 
cytometry and differential cell counting. To induce pulmonary neutrophilia, 0.5 µg 
IL-17A was introduced intranasally to groups of age-matched female Il17rd + / +  
and Il17rd − / −  mice as previously described32. After 4 h, bronchoalvelolar lavage 
(BAL) was performed and cellular infiltration into the lung was quantified by  
differential cell counts on BALs as previously described33. Lung tissue was  
perfused and fixed in 10% formalin saline. Paraffin-embedded sections were 
stained with hematoxylin and eosin to assess leukocyte infiltration and  
pulmonary inflammation.
Lentiviral production and transduction. HEK293T cells were seeded 
(2×105 cells ml − 1; 3 ml) in six-well plates and grown for 24 h to~80% confluency. 
Cells were transfected using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions with the packaging plasmid pCMV-dR 8.91 (1 µg), 
envelope plasmid VSV-G (1 µg) and IL-17RD sh-pLKO.1 vector (2 µg) or control 
shRNA (Sigma Aldrich, St. Louis, USA): IL-17RD shRNA 5′- CCGGCCAGTCTT 
GGAGAAATTTGATCTCGAGATCAAATTTCTCCAAGACTGGTTTTTG-3′ 
(NM_017563.1-1819s1c1). Conditioned medium was changed 24 h post transfec-
tion and replaced with fresh growth medium containing 30% (v/v) FBS for a fur-
ther 24 h. The lentivirus-containing medium was harvested and replenished every 
24 h for 72 h. U373 cells, seeded (2×105 cells ml − 1; 3 ml) in six-well plates, were 
transduced with 600 µl lentivirus-containing medium with polybrene (8 µg ml − 1) 
and incubated at 37oC for 24 h before positive selection of cells with integrated 
shRNA constructs with puromycin (8 µg ml − 1).
Luciferase reporter assay. HeLa and HEK293 cells were seeded (0.8×105 and 
1.5×105 cells ml − 1, respectively) in 96-well plates (200 µl per well) for 24 h. Cells 
were then transfected using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instruction, with luciferase reporter construct (80 ng), constitutively 
expressed TK Renilla-luciferase reporter construct (phRL-TK) (20 ng) (Promega 
Biosciences) and varying amounts of expression constructs. Total DNA was kept 
constant (200 ng per well) using the appropriate empty vector. For siRNA experi-
ments, cells were transfected using Lipofectamine, with siRNA targeting IL-17RD 
(sense sequence: 5′-GGAGCAAACUACAGAGAUGTT-3′) or with scrambled 
siRNA (sense sequence: 5′-GGACAGAACACUAGAUGAGTT-3′) (10 nM and 
20 nM) (Ambion). Cell extracts were generated 24 h (or 48 h for siRNA) post  
transfection using reporter lysis buffer (Promega Biosciences) and extracts were 
assayed for firefly luciferase and Renilla-luciferase activity using the luciferase  
assay system (Promega Biosciences) and coelenterazine (0.1 µg ml − 1 Insight 
Biotechnology Ltd.), respectively. Luminescence was monitored with the Glomax 
microplate luminometer (Promega).
Enzyme-linked immunosorbent assay. MEFs or U373 cells, stably transfected 
with IL-17RD-specific shRNA or control shRNA, were seeded (3×105 cells ml − 1; 
200 µl) in 96-well plates and grown for 24 h. Cells were subsequently stimulated 
with various ligands for the indicated time points as described in figure legends. 
PBMCs were seeded (1×106 cells ml − 1; 200 µl) in 96-well plates and after 2 h were 
transfected with siRNA (10 or 20 nM diluted in serum-free RPMI) using Lipo-
fectamine 2000. An identical second transfection of siRNA with Lipofectamine 
2000 was carried out 24 h later. After a further 24 h cells were stimulated with 
IL-17A (100 ng ml − 1) for 24 h. Conditioned media from cells was measured for 
levels of murine IL-6, KC and MIP-2 or human IL-6, IL-8 and MIP-2 by sandwich 
enzyme-linked immunosorbent assay (ELISA; IL-6 and IL-8 DuoSet kits (R&D 
Systems), MIP-2 kits (Peprotech)). ELISA was also performed on lavage fluid  
from mice treated with PBS or IL-17A by intraperitoneal injection. Lavages were 
concentrated using Amicon-4 centrifugal filters (Millipore) before ELISA analysis.
Electrophoretic mobility shift assay. U373 cells, stably transduced with IL-17RD 
shRNA or control shRNA, and MEFs were grown in 90-mm dishes for 24 h. Cells 
were then stimulated with IL-17A (100 ng ml − 1) for various times. Nuclear extracts 
were generated as previously described34. Nuclear protein (10 µg) was incubated 
with LI-COR IRDye 700 labelled oligonucleotide containing the NF-κB binding 
site 5′-AGTTGAGGGGACTTTCCCAGGC-3′ (κB site underlined), according 
to the manufacturer’s instructions. For competitive analysis, unlabelled oligo-
nucleotide was added to the extracts for 15 min before incubation with labelled 
oligonucleotide. All incubations were subjected to electrophoresis on a 4% native 
polyacrylamide gel for 2 h at 110 V and subsequently analysed and images captured 
using the Odyssey Infrared Imaging System (LI-COR Biosciences).
Statistical analysis. Data are expressed relative to untreated cells and are the 
means ± s.e.m. of triplicate determinations from three independent experiments. 
For comparison between two groups, paired Student’s t test (two tail, one type)  
was used. A P-value of  < 0.05 was considered significant.
Genotyping of mice, co-immunoprecipitations, immunoblotting, RNA  
isolation, quantitative PCR, flow cytometry and slide preparation methodology  
are detailed in the Supplementary Method section. 
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